|
|
|
|
A top 10 biopharmaceutical company wanted to expand its site list in a priority indication and better understand how existing sites in their database performed. Find out what happened next.
|
|
|
|
|
As a mid-sized biopharmaceutical company embarked on an upcoming rare disease clinical trial, they struggled with patient recruitment and site selection. Explore how the sponsor chose high-performing sites based on reliable data to set their trial up for success.
|
|
|
|
|
Generative AI is offering a breakthrough with the creation of synthetic data. Medidata’s Simulants generative AI algorithm exemplifies this innovation, leveraging one of the industry’s largest standardized trial data repositories to produce high-fidelity, regulatory-grade synthetic datasets.
|
|
|
|
|
Examine the growing role of external control arms in clinical trials, including the distinctions between control groups that use real-world data and those that use historical clinical trial data.
|
|
|
|
|
This white paper features a series of case studies discussing the concept of the Synthetic Control Arm (SCA), a type of external control that's generated to improve the interpretation of uncontrolled trials, which can enable better product development decisions.
|
|
|
|
|
Clinical trials face persistent challenges in patient recruitment, retention, and protocol complexity. To address these obstacles, the integration of standardized, regulatory-grade clinical trial data has become central to advancing trial design and execution.
|
|
|
